Home › Hidradenitis Suppurativa
Hidradenitis Suppurativa clinical trials recruiting in the U.S.
30 studies for Hidradenitis Suppurativa are recruiting participants at sites across the United States.
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
Cities with the most studies
- Boston, MA9 studies
- Birmingham, AL7 studies
- New York City, NY7 studies
- Miami, FL6 studies
- Tampa, FL6 studies
- Durham, NC6 studies
- Bowling Green, KY5 studies
- Phoenix, AZ5 studies
- The Bronx, NY5 studies
- Baton Rouge, LA5 studies
- Dallas, TX4 studies
- Evanston, IL4 studies
- St. Louis, MO4 studies
- Minneapolis, MN4 studies
- Santa Clarita, CA4 studies
- Detroit, MI3 studies
- Houston, TX3 studies
- Hartford, CT3 studies
- Baltimore, MD3 studies
- Troy, MI3 studies
- Sandy Springs, GA3 studies
- Evansville, IN3 studies
- Oklahoma City, OK3 studies
- Kendall, FL3 studies
- Atlanta, GA3 studies
- Indianapolis, IN3 studies
- Cleveland, OH3 studies
- Los Angeles, CA3 studies
- San Antonio, TX3 studies
- New Orleans, LA3 studies
- Chicago, IL3 studies
- West Lafayette, IN3 studies
- Philadelphia, PA3 studies
- Norfolk, VA3 studies
- San Francisco, CA3 studies
- Scottsdale, AZ3 studies
By state
- Alabama7 studies
- Arizona6 studies
- California13 studies
- Connecticut3 studies
- Florida10 studies
- Georgia8 studies
- Illinois6 studies
- Indiana7 studies
- Kentucky7 studies
- Louisiana6 studies
- Maryland3 studies
- Massachusetts10 studies
- Michigan7 studies
- Minnesota4 studies
- Missouri6 studies
- New York10 studies
- North Carolina7 studies
- Ohio5 studies
- Oklahoma4 studies
- Pennsylvania6 studies
- South Carolina3 studies
- Tennessee3 studies
- Texas9 studies
- Utah3 studies
- Virginia4 studies
Recently updated studies
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Nov 13, 2026 · NCT07213973Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06855498A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Nov 10, 2026 · NCT07855276Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07830329An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 9, 2026 · NCT07665437ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Oct 29, 2026 · NCT07783542A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 19, 2026 · NCT07766005A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07225569Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07828860Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07170917Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT07689188Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 9, 2026 · NCT07049575Regulation of Inflammatory Genes in Hidradenitis Suppurativa
RecruitingObservational study
Ages 18 to 89 · All sexes · Updated Sep 21, 2026 · NCT05507125A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 18, 2026 · NCT06888193Targeting Nociceptors in Hidradenitis Suppurativa
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 10, 2026 · NCT05403710Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06058520Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06326476A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975Myriad™ Augmented Soft Tissue Reconstruction Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05243966The Safety and Efficacy of Roflumilast Foam in HS
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07263230Pelashield™ PainGuard™ vs Restrata® in HS Surgery
Recruiting
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07316192Radiotherapy for Refractory Hidradenitis Suppurativa
Recruiting
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT07414550Clinical and Biological Characteristics of Hidradenitis Suppurativa
RecruitingObservational studyHealthy volunteers welcome
Ages 13 and older · All sexes · Updated May 4, 2026 · NCT03967600Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
RecruitingObservational study
Ages 10 and older · All sexes · Updated Apr 29, 2026 · NCT04115566A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
RecruitingObservational study
Ages 18 to 71 · All sexes · Updated Apr 16, 2026 · NCT07123038From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.